Orofacial Dyskinesia, Cognitive Function and Medication

1986 ◽  
Vol 149 (2) ◽  
pp. 216-220 ◽  
Author(s):  
Philip Thomas ◽  
Ralph McGuire
Keyword(s):  
Regression Analysis ◽  
Cognitive Function ◽  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
The Other ◽  
Orofacial Dyskinesia ◽  
Duration Of Treatment ◽  
Delayed Recall ◽  
Abnormal Involuntary Movement Scale ◽  
Abnormal Movements

The presence of tardive dyskinesia in a sample of 43 patients with schizophrenia and 37 psychopaths who had been hospitalised for many years and exposed to large amounts of medication was assessed while testing their cognitive function. Subjects who showed no evidence of abnormal movements performed significantly better on the test of delayed recall, but there were no differences in performance on any of the other tests of cognitive function used. Multiple regression analysis revealed that age and the total lifetime dose of neuroleptic medication received (in chlorpromazine equivalents) were the only variables to predict the Abnormal Involuntary Movement Scale score, although a large amount of variance in this variable was unaccounted for. The duration of treatment with neuroleptics did not predict AIMS score.

Heterogeneity of Tardive Dyskinesia

1988 ◽  
Vol 152 (2) ◽  
pp. 253-259 ◽  
Author(s):  
William M. Glazer ◽  
Hal Morgenstern ◽  
Donna Niedzwiecki ◽  
Jeffrey Hughes
Keyword(s):  
Tardive Dyskinesia ◽  
Mental Health Center ◽  
Involuntary Movement ◽  
Living Alone ◽  
Psychiatric Medication ◽  
New Haven ◽  
Abnormal Movements ◽  
Clinical Syndromes ◽  
Severity Scores ◽  
Orofacial Movement

To determine whether tardive dyskinesia (TD) is a single abnormal movement syndrome or multiple syndromes involving different anatomical areas, we examined 228 out-patients diagnosed with TD at the Connecticut Mental Health Center in New Haven. Application of factor analysis to the seven anatomical severity scores of the Abnormal Involuntary Movement Scale yielded three statistically independent factors involving abnormal movements primarily of the jaw-tongue, face-lips, and extremities-trunk. Using logistic regression to predict the severity of these factors, we found that the severity of the orofacial scores was positively associated with age, schizoaffective or affective disorder, and living alone, while severity of non-orofacial movement was positively associated with current neuroleptic dose, non-use of psychiatric medication, and living alone. Our findings suggest that orofacial and non-orofacial dyskinetic movements may involve distinct clinical syndromes of TD, each having a different set of prognostic and, possibly, aetiological determinants.

Diazepam in Tardive Dyskinesia

1983 ◽  
Vol 17 (7-8) ◽  
pp. 523-527 ◽  
Author(s):  
Stanley S. Weber ◽  
Robert L. Dufresne ◽  
Robert E. Becker ◽  
Peter Mastrati
Keyword(s):  
Tardive Dyskinesia ◽  
Rating Scale ◽  
Case Reports ◽  
Involuntary Movement ◽  
Similar Degree ◽  
Brief Psychiatric Rating Scale ◽  
Abnormal Movements ◽  
Psychiatric Rating ◽  
Motor Movements ◽  
Psychiatric Rating Scale

Tardive dyskinesia, a syndrome of involuntary motor movements, can be a permanent consequence of the long-term use of antipsychotic drugs. While there is no well-established drug treatment, case reports and the results of a few clinical studies suggest that drugs that facilitate the GABA-ergic system may decrease the abnormal movements. One such class of drugs is the benzodiazepines. We administered diazepam to 13 subjects in a 24-week, crossover design study. Tardive dyskinesia and psychopathology were assessed by blind raters using the Abnormal Involuntary Movement Scale and the Brief Psychiatric Rating Scale (BPRS). The means of all movement measurements improved from the baseline, with orofacial, subtotal, symptom severity, and total reaching significance. However, we were unable to demonstrate a drug effect; the patients improved to a similar degree whether or not they received diazepam. Their psychiatric disorders did not worsen with diazepam administration and, in fact, improved slightly; the activation factor of the BPRS was significantly improved over baseline. Our results suggest that diazepam is not effective in managing the movements of tardive dyskinesia and that behavior modification strategies be investigated to help patients control symptoms.

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia

2005 ◽  
Vol 77 (2-3) ◽  
pp. 119-128 ◽  
Author(s):  
Georges M. Gharabawi ◽  
Cynthia A. Bossie ◽  
Robert A. Lasser ◽  
Ibrahim Turkoz ◽  
Stephen Rodriguez ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Rating Scale ◽  
Extrapyramidal Symptom ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale ◽  
Symptom Rating

Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia

2020 ◽  
Vol 40 (4) ◽  
pp. 373-380 ◽  
Author(s):  
Stanley N. Caroff ◽  
Shirley H. Leong ◽  
Christopher B. Roberts ◽  
Rosalind M. Berkowitz ◽  
E. Cabrina Campbell
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale

scholarly journals Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia

CNS Spectrums ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 152-152
Author(s):  
Leslie Citrome ◽  
Leslie Lundt ◽  
Chirag Shah ◽  
Tara Carmack
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Real Life ◽  
Meaningful Improvement ◽  
Once Daily ◽  
Abnormal Involuntary Movement Scale ◽  
Clinical Measure ◽  
Long Term Study ◽  
Using Data ◽  
Post Hoc

AbstractObjectiveThe Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1–7) is usually the primary efficacy measure in tardive dyskinesia (TD) clinical trials. However, item 8 of the AIMS (clinician’s global impression of severity) might also be an appropriate assessment in real-life healthcare settings. To explore the potential of item 8 as a clinical measure, post hoc analyses were conducted using data from a long-term study of valbenazine, an approved TD medication.MethodsIn KINECT 4 (NCT02405091), adults with TD received once-daily valbenazine (40 or 80 mg) for 48 weeks. Analyses included two sets of AIMS item 8 scores: based on investigators ratings of item 8 using protocol-defined descriptors; and based on investigators highest scores from items 1–7 (analyzed post hoc). Shift analyses included an improvement from score =3 at baseline (moderate or severe) to score =2 at Week 48 (none to mild).ResultsAt baseline in all participants (N=163), AIMS item 8 mean scores were 3.2 (protocol) and 3.3 (post hoc). In participants with a score =3 at baseline per investigators ratings using protocol-defined descriptors, 95.9% [94/98] shifted to a score =2 by Week 48. A similar result (93.9% [93/99]) was found when item 8 was based on investigators highest scores from items 1–7.ConclusionShift analyses using AIMS item 8 scores indicated that most participants in KINECT 4 had a clinically meaningful improvement after 48 weeks of once-daily treatment with valbenazine. AIMS item 8 may be an appropriate clinical measure for assessing changes in TD severity.FundingNeurocrine Biosciences, Inc.

Assessment of Tardive Dyskinesia Using the Abnormal Involuntary Movement Scale

1985 ◽  
Vol 173 (6) ◽  
pp. 353-357 ◽  
Author(s):  
RICHARD D. LANE ◽  
WILLIAM M. GLAZER ◽  
THOMAS E. HANSEN ◽  
WILLIAM H. BERMAN ◽  
STEPHEN I. KRAMER
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale

scholarly journals Randomized controlled trial of deutetrabenazine for tardive dyskinesia

Neurology ◽  
2017 ◽  
Vol 88 (21) ◽  
pp. 2003-2010 ◽  
Author(s):  
Hubert H. Fernandez ◽  
Stewart A. Factor ◽  
Robert A. Hauser ◽  
Joohi Jimenez-Shahed ◽  
William G. Ondo ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Primary Endpoint ◽  
Rating Scale ◽  
Involuntary Movement ◽  
Controlled Trial ◽  
Treatment Success ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Abnormal Movements ◽  
Global Impression Of Change

Objective:To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD).Methods:One hundred seventeen patients with moderate to severe TD received deutetrabenazine or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an Abnormal Involuntary Movement Scale (AIMS) score of ≥6 assessed by blinded central video rating, stable psychiatric illness, and stable psychoactive medication treatment. Primary endpoint was the change in AIMS score from baseline to week 12. Secondary endpoints included treatment success at week 12 on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change.Results:For the primary endpoint, deutetrabenazine significantly reduced AIMS scores from baseline to week 12 vs placebo (least-squares mean [standard error] −3.0 [0.45] vs −1.6 [0.46],p= 0.019). Treatment success on CGIC (48.2% vs 40.4%) favored deutetrabenazine but was not significant. Deutetrabenazine and placebo groups showed low rates of psychiatric adverse events: anxiety (3.4% vs 6.8%), depressed mood/depression (1.7% vs 1.7%), and suicidal ideation (0% vs 1.7%, respectively). In addition, no worsening in parkinsonism, as measured by the Unified Parkinson's Disease Rating Scale motor subscale, was noted from baseline to week 12 in either group.Conclusions:In patients with TD, deutetrabenazine was well tolerated and significantly reduced abnormal movements.Classification of evidence:This study provides Class I evidence that in patients with TD, deutetrabenazine reduces AIMS scores.

Sign in / Sign up

Export Citation Format

Share Document